TVARDI THERAPEUTICS INC (TVRD) Stock Price, Quote, News and Overview
NASDAQ:TVRD - Nasdaq - US1407553072 - Common Stock - Currency: USD
TVRD Quote, Performance and Key Statistics
29.83
+2.48 (+9.09%)
The current stock price of TVRD is 29.83 USD. In the past month the price increased by 14.25%.
TVRD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 58.09 | 757.57B | ||
| JNJ | JOHNSON & JOHNSON | 15.6 | 377.32B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.73 | 306.33B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.57 | 239.06B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.49 | 222.42B | ||
| MRK | MERCK & CO. INC. | 10.74 | 210.10B | ||
| PFE | PFIZER INC | 7.9 | 144.12B | ||
| SNY | SANOFI-ADR | 10.67 | 118.22B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.45 | 96.34B | ||
| GSK | GSK PLC-SPON ADR | 8.6 | 77.46B | ||
| ZTS | ZOETIS INC | 25.86 | 69.30B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 62.67 | 46.98B |
Related stock screener links
About TVRD
Company Profile
Tvardi Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Sugar Land, Texas and currently employs 10 full-time employees. The company went IPO on 2014-01-31. Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Company Info
TVARDI THERAPEUTICS INC
3 Sugar Creek Ctr Blvd, Ste 525
Sugar Land TEXAS US
Employees: 10
Phone: 17134898654
TVARDI THERAPEUTICS INC / TVRD FAQ
What is the stock price of TVARDI THERAPEUTICS INC today?
The current stock price of TVRD is 29.83 USD. The price increased by 9.09% in the last trading session.
What is the ticker symbol for TVARDI THERAPEUTICS INC stock?
The exchange symbol of TVARDI THERAPEUTICS INC is TVRD and it is listed on the Nasdaq exchange.
On which exchange is TVRD stock listed?
TVRD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TVARDI THERAPEUTICS INC stock?
11 analysts have analysed TVRD and the average price target is 54.01 USD. This implies a price increase of 81.07% is expected in the next year compared to the current price of 29.83. Check the TVARDI THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TVARDI THERAPEUTICS INC worth?
TVARDI THERAPEUTICS INC (TVRD) has a market capitalization of 279.21M USD. This makes TVRD a Micro Cap stock.
How many employees does TVARDI THERAPEUTICS INC have?
TVARDI THERAPEUTICS INC (TVRD) currently has 10 employees.
Is TVARDI THERAPEUTICS INC (TVRD) expected to grow?
The Revenue of TVARDI THERAPEUTICS INC (TVRD) is expected to decline by -86.46% in the next year. Check the estimates tab for more information on the TVRD EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TVARDI THERAPEUTICS INC (TVRD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TVRD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TVRD, evaluating the profitability, health, valuation and growth aspects
- TVARDI THERAPEUTICS INC (TVRD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TVARDI THERAPEUTICS INC (TVRD) Sales and EPS estimates to see what analysts future expectations are.
- TVARDI THERAPEUTICS INC (TVRD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TVARDI THERAPEUTICS INC (TVRD) Insider and Institutional Ownership to learn about the owners and their transactions.
- TVARDI THERAPEUTICS INC (TVRD) Stock Chart to make your own analysis
- TVARDI THERAPEUTICS INC (TVRD) Latest news and press-releases to stay up to date.
Does TVARDI THERAPEUTICS INC (TVRD) stock pay dividends?
TVRD does not pay a dividend.
When does TVARDI THERAPEUTICS INC (TVRD) report earnings?
TVARDI THERAPEUTICS INC (TVRD) will report earnings on 2025-08-12, after the market close.
What is the Price/Earnings (PE) ratio of TVARDI THERAPEUTICS INC (TVRD)?
TVARDI THERAPEUTICS INC (TVRD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-29.6).
What is the Short Interest ratio of TVARDI THERAPEUTICS INC (TVRD) stock?
The outstanding short interest for TVARDI THERAPEUTICS INC (TVRD) is 2.43% of its float. Check the ownership tab for more information on the TVRD short interest.
TVRD Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to TVRD.
TVRD Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to TVRD. TVRD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TVRD Financial Highlights
Over the last trailing twelve months TVRD reported a non-GAAP Earnings per Share(EPS) of -29.6. The EPS increased by 63.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -115.7% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TVRD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to TVRD. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -84.42% and a revenue growth -86.46% for TVRD